104 related articles for article (PubMed ID: 11410111)
1. Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?
Rustemeijer C; Schouten JA; Voerman HJ; Beynen AC; Donker AJ; Heine RJ
Clin Sci (Lond); 2001 Jul; 101(1):29-35. PubMed ID: 11410111
[TBL] [Abstract][Full Text] [Related]
2. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
[TBL] [Abstract][Full Text] [Related]
3. Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?
Ng TW; Watts GF; Stuckey BG; Ching HL; Chan DC; Uchida Y; Sakai N; Yamashita S; Martins IJ; Redgrave TG; Barrett PH
Clin Endocrinol (Oxf); 2005 Dec; 63(6):650-6. PubMed ID: 16343099
[TBL] [Abstract][Full Text] [Related]
4. Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
Dullaart RP; de Vries R; Voorbij HA; Sluiter WJ; van Tol A
Eur J Clin Invest; 2009 Mar; 39(3):200-3. PubMed ID: 19260949
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
Donnelly LA; Palmer CN; Whitley AL; Lang CC; Doney AS; Morris AD; Donnan PT
Pharmacogenet Genomics; 2008 Apr; 18(4):279-87. PubMed ID: 18334912
[TBL] [Abstract][Full Text] [Related]
6. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
7. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
8. [Insulin requirement in patients with type 1 diabetes with reduced renal function: human insulin versus analogue insulin].
Hasslacher C; Vogt C; Raupp D; Dreyhaupt J
Dtsch Med Wochenschr; 2007 Nov; 132(47):2500-4. PubMed ID: 18027324
[TBL] [Abstract][Full Text] [Related]
9. Diacylglycerol-induced improvement of whole-body insulin sensitivity in type 2 diabetes mellitus: a long-term randomized, double-blind controlled study.
Li D; Xu T; Takase H; Tokimitsu I; Zhang P; Wang Q; Yu X; Zhang A
Clin Nutr; 2008 Apr; 27(2):203-11. PubMed ID: 18314230
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
Goldberg RB; Fonseca VA; Truitt KE; Jones MR
Arch Intern Med; 2008 Jul; 168(14):1531-40. PubMed ID: 18663165
[TBL] [Abstract][Full Text] [Related]
12. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
Tenenbaum A; Motro M; Fisman EZ; Adler Y; Shemesh J; Tanne D; Leor J; Boyko V; Schwammenthal E; Behar S
Eur Heart J; 2005 Oct; 26(19):2032-8. PubMed ID: 15872029
[TBL] [Abstract][Full Text] [Related]
13. Plasma cholinesterase activity in patients with uterine cervical cancer during radiotherapy.
Bradamante V; Smigovec E; Buković D; Geber J; Matanić D
Coll Antropol; 2000 Dec; 24(2):373-80. PubMed ID: 11216405
[TBL] [Abstract][Full Text] [Related]
14. Effect of anticholesterol therapy on soluble ICAM-1 in chronic stroke patients with hyperlipidemia.
Tomiyasu H; Ishikawa K; Yamamoto M; Hata T; Ohta T; Kitagawa Y; Shinohara Y
Tokai J Exp Clin Med; 2005 Apr; 30(1):63-9. PubMed ID: 15952300
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
16. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure.
Smooke S; Horwich TB; Fonarow GC
Am Heart J; 2005 Jan; 149(1):168-74. PubMed ID: 15660049
[TBL] [Abstract][Full Text] [Related]
17. Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension.
Park H; Hasegawa G; Obayashi H; Fujinami A; Ohta M; Hara H; Adachi T; Tamaki S; Nakajima Y; Kimura F; Ogata M; Fukui M; Yoshikawa T; Nakamura N
Clin Chim Acta; 2006 Dec; 374(1-2):129-34. PubMed ID: 16857181
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.
Juretić D; Motejlkova A; Kunović B; Rekić B; Flegar-Mestrić Z; Vujić L; Mesić R; Lukac-Bajalo J; Simeon-Rudolf V
Acta Pharm; 2006 Mar; 56(1):59-68. PubMed ID: 16613735
[TBL] [Abstract][Full Text] [Related]
19. Pseudocholinesterase in alloxan-diabetic rats.
Oresković K; Kunec-Vajić E
Res Commun Chem Pathol Pharmacol; 1992 Oct; 78(1):117-20. PubMed ID: 1462046
[TBL] [Abstract][Full Text] [Related]
20. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients.
Vaisi-Raygani A; Rahimi Z; Nomani H; Tavilani H; Pourmotabbed T
Clin Biochem; 2007 Oct; 40(15):1150-6. PubMed ID: 17689519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
